Thomas A. Shea Joins EPIRUS Biopharmaceuticals as Chief Financial Officer

BOSTON--(BUSINESS WIRE)--EPIRUS Biopharmaceuticals, Inc. (EPIRUS), a privately held biotechnology company focused on the development and production of biosimilar products in and for major emerging markets, today announced the appointment of Thomas Shea as Chief Financial Officer (CFO).

"We are very pleased to welcome Tom to the EPIRUS team," said Amit Munshi, CEO of EPIRUS. "Tom's extensive financial experience in the pharmaceutical and biotechnology industries will be critical as we advance our pipeline and pursue partnerships in multiple markets."

As CFO, Mr. Shea will oversee EPIRUS' financial planning and analysis, technical accounting, controllership, treasury, tax, insurance, investor relations, human resources and facilities functions.

Mr. Shea brings almost 30 years of experience leading finance organizations, directing fund raising activities, structuring complex partnerships, and planning and executing IPO activities for high growth biopharmaceutical companies. Most recently, he served as CFO and Treasurer of Euthymics Bioscience, Neurovance Inc, and EBI Life Sciences, three privately held, affiliated companies. Previously, he spent 6 years as CFO of Tolerx, Inc. He also served as CFO of Cubist Pharmaceuticals, Inc. where he was integral to the Company's IPO, and in a variety of senior finance roles at ImmuLogic Pharmaceutical Corp. Mr. Shea received his MBA from Suffolk University in 1997 and his B.S. in Accounting/Law from Babson College in 1981.

"I am very impressed with the progress EPIRUS has made in such a short period of time," said Mr. Shea. "The company's innovative business strategy and portfolio has the potential to help a large number of patients around the world and to build sustained value."

About EPIRUS Biopharmaceuticals

EPIRUS is focusing on the central development of a broad pipeline of biosimilar monoclonal antibodies and therapeutic proteins, optimized for use within the SCALE™ disposable manufacturing system, and designed to be deployed in an "In Market, For Market" ™ manufacturing configuration.

SCALE is a modular state-of-the-art manufacturing process utilizing the latest in disposable technology. It is ideally suited for use as a localized In Market, For Market manufacturing solution designed to provide speed to market, low capital cost, campaign flexibility and utilization rates which can be tailored to local and or regional needs. This innovative product platform aims to enable localized manufacturing in emerging economies where EPIRUS is developing partnerships combining public and private sector financial support and expertise. EPIRUS is focusing on a range of emerging markets, including, Brazil, South Africa, Turkey, Russia, MENA, and the ASEAN markets.

EPIRUS envisions the creation of unprecedented patient access to biosimilar therapeutics through efficient global development and local production of these important medicines.

Contacts

Media Contact:
EPIRUS Biopharmaceuticals, Inc.
Amit Munshi, 617-600-3497

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.